Synthetic Biologics, Inc. is a clinical phase company. The company develops therapies to protect intestinal microbiomas while targeting specific pathogenic diseases. The main candidates for Phase II companies are SYN-010, which aims to reduce the effect of methane-producing methane on intestinal microbiomas to treat the cause of irritable bowel syndrome (IBS-C) and SYN-004. which is designed to protect intestinal microbiomas (gastrointestinal (GI) microflora) from the effects of some intravenous antibiotics (IV) commonly used to prevent C. difficile infections (CDI) and antibiotic-related diarrhea (AAD). Other product candidates include SYN-007, SYN-006, SYN-005, SYN-200, and SYN-020. The company is also developing preclinical therapy with monoclonal antibodies to prevent and treat pertussis, and therapists are in the discovery stage to treat phenylketonuria (PKU).

How Synthetic Biologics, Inc. Can Impact Your Portfolio Volatility

If you are interested in Synthetic Biologics, Inc.syn stock at, consider beta (a measure of stock price volatility) to find out how stocks can affect your portfolio. In modern financial theory, instability is seen as a measure of risk. Investors can imagine instability as falling into two main categories. The first category is corporate variability. You can handle this by limiting your exposure to certain stocks. Another type that cannot be diversified is the instability of the whole market. Every share in the market is subject to this instability, which is related to the fact that stock prices depend on an efficient market.

Some stocks mimic market volatility, while others subdue, increase, or do not correlate with price movements. Beta can be a useful tool to understand the extent to which stocks are influenced by market risk (volatility). However, Warren Buffett said in his 2014 letter to investors that “volatility is not at all identical to risk.” Beta is useful, but it is not the only indicator to consider. To use Beta as an investor, you must first understand that the Common Market has a beta. Every stock with more than one beta is considered to be more unstable from the market, while stocks with beta are more or less volatile or correlate poorly with the market.

What does SYN’s beta value mean to investors?

Zooming in on Synthetic Biologics syn stock we see it has a five year beta of 1.70. This is above 1, so historically its share price has been influenced by the broader volatility of the stock market. If the past is any guide, we would expect that Synthetic Biologics shares will rise quicker than the markets in times of optimism, but fall faster in times of pessimism. Beta is worth considering, but it’s also important to consider whether Synthetic Biologics is growing earnings and revenue.  If you want to know more stock information like lctx stock, you can visit at